Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyBlue Cross Blue Shield MA antihyperlipidemics Prio…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - MassachusettsPolicy 013

    Antihyperlipidemic agents prior authorization and quantity limits

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 013 alerts

    Get alerted when Policy 013 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, quantity limit, and clinical coverage criteria for specified antihyperlipidemic medications for BCBSMA commercial members (excludes Medicare Advantage). Applies to medications covered under pharmacy and/or medical benefits per formulary status.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyAntihyperlipidemic agents prior authorization and quantity limits
    Policy CodePolicy 013
    Change TypeAdded Repatha indicationadded Tryngolzarevised statin trial requirement
    Effective Date
    Next Review Date
    Key ActionPrior authorization must be submitted and meet listed initial or continuation criteria with supporting documentation (labs, treatment history, and specialist evaluation when required).
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Added expanded indication for Repatha.

    Addition of Tryngolza to the policy.

    Updated to remove trial of three (3) statins for Praluent and Repatha.

    12 monthstypical approval length
    3 monthsLeqvio initial approval
    MultiplePA drugs
    ≤3 monthslab recency (continuation)
    ≤12 monthslab recency (initial)
    ≥880 mg/dLTryngolza TG threshold

    Coverage Criteria for Antihyperlipidemic Agents

    Evkeeza - Initial therapy

    Covered when ALL of the following are met

    Evkeeza coverage criteria: 1) A confirmed diagnosis of Homozygous Familial Hypercholesterolemia (HoFH). 2) Used as adjunct therapy to diet and maximally tolerated statin therapy in combination with ezetimibe. 3) Recent cholesterol labs with values within the last 12 months. 4) Current treatment with Praluent or Repatha unless clinically contraindicated to PCSK9 inhibitors.

    Juxtapid - Initial therapy

    Covered when ALL of the following are met

    Juxtapid coverage criteria: 1) A confirmed diagnosis of Homozygous Familial Hypercholesterolemia (HoFH). 2) Used as adjunct therapy to diet and maximally tolerated statin therapy in combination with ezetimibe. 3) Recent cholesterol labs within the last 12 months with values OR patient is receiving LDL apheresis.

    Leqvio - Initial and continuation

    Covered when ALL of the following are met

    Leqvio initial approval: 1) A confirmed diagnosis of ONE of: primary hyperlipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), or established cardiovascular disease. 2) Age > 18 years. 3) Evaluation in a lipid program staffed by a board-certified cardiologist or endocrinologist. 4) Recent LDL labs with values within the last 12 months. 5) Used as adjunct to diet and maximally tolerated statin therapy in combination with ezetimibe OR previous treatment failure with 3 statin medications (at least 2 high potency) in combination with ezetimibe. 6) Previous treatment failure with Repatha.

    Initial approval length: 3 months (encompassing one 6-month shot).

    Leqvio continuation criteria: 1) Adherence to current therapy verified with claims data. 2) Current (<3 months) submitted lab values show maintained improvement in LDL levels.

    Length of approval: 12 months.

    Nexletol/Nexlizet - Initial therapy

    Covered when ALL of the following are met

    Nexletol/Nexlizet coverage criteria: 1) A confirmed diagnosis of ONE of: Heterozygous Familial Hypercholesterolemia (HeFH), established cardiovascular disease, or at high risk for a cardiovascular disease event without established CVD. 2) Evaluation in a lipid program staffed by a board-certified cardiologist or endocrinologist. 3) Used as adjunct therapy to diet and maximally tolerated statin therapy (applicable when diagnosis is HeFH).

    Praluent - Initial and continuation

    Covered when ALL of the following are met

    Praluent initial approval: 1) A confirmed diagnosis of HeFH or HoFH or established cardiovascular disease. 2) Evaluation in a lipid program staffed by a board-certified cardiologist or endocrinologist. 3) Age > 18 years. 4) Recent LDL labs with values within the last 12 months. 5) Used as adjunct therapy to diet and maximally tolerated statin therapy in combination with ezetimibe. 6) Previous treatment failure with Repatha.
    Praluent continuation: 1) Adherence to current therapy verified with claims data. 2) Current (<3 months) submitted lab values show maintained improvement in LDL levels.

    Length of approval: 12 months.

    Repatha - Initial and continuation

    Covered when ALL of the following are met

    Repatha indication options: 1) A confirmed diagnosis of ONE of: Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), or established cardiovascular disease. OR 2) Patient is at increased risk for major adverse cardiovascular events (MACE) due to at least one of: coronary artery disease, peripheral arterial disease, atherosclerotic cerebrovascular disease, or diabetes mellitus.
    Repatha additional criteria: Recent LDL labs with values within the last 12 months AND used as adjunct therapy to a low-fat diet.
    Repatha continuation: 1) Adherence to current therapy verified with claims data. 2) Current (<3 months) submitted lab values show maintained improvement in triglyceride levels. 3) Used as adjunct therapy to a low-fat diet.

    Length of approval: 12 months.

    Initial Approval - General

    Initial Approval (general lipid-lowering therapies)

    Diagnosis or established disease: A confirmed diagnosis of ONE of: (a) Heterozygous Familial Hypercholesterolemia (HeFH); (b) Homozygous Familial Hypercholesterolemia (HoFH); (c) Established cardiovascular disease. OR patient is at increased risk for MACE due to at least ONE of: (a) Coronary artery disease; (b) Peripheral arterial disease; (c) Atherosclerotic cerebrovascular disease; (d) Diabetes mellitus.

    From initial approval section

    Supporting requirements: Recent LDL labs within the last 12 months AND used as adjunct therapy to a low-fat diet.Labs <12 months

    Applies to initial approval

    Continuation Therapy

    Continuation of therapy (general)

    Adherence and labs: Adherence to current therapy verified with claims data AND current (<3 months) submitted lab values show maintained improvement in triglyceride or LDL levels depending on the agent.Labs <3 months

    Length of approval: 12 months

    Adjunct therapy: Used as adjunct therapy to a low-fat diet (and for some agents, adjunct to diet and maximally tolerated statin therapy in combination with ezetimibe).

    Continuation criteria include diet adjunct

    Tryngolza Initial Approval

    Covered when ALL of the following are met

    Diagnosis confirmation: Confirmed diagnosis of Familial chylomicronemia syndrome documented by genetic mutation analysis.

    Required for Tryngolza

    Specialist program evaluation: Evaluation in a lipid program staffed by a board-certified cardiologist or endocrinologist.

    Required for Tryngolza

    Triglyceride level: Fasting triglyceride levels of >=880 mg/dL within the last twelve (12) months.>=880 mg/dL

    Required for Tryngolza initial approval

    Adjunct therapy: Used as adjunct therapy to diet.

    Specialist and adjunct therapy requirements

    Applies to agents that require specialist evaluation

    Lipid program evaluation: Evaluation in a lipid program staffed by a board-certified cardiologist or endocrinologist.

    Listed in policy

    Adjunct to maximally tolerated therapy: Used as adjunct therapy to diet and maximally tolerated statin therapy in combination with ezetimibe.

    Listed in policy

    Certain commonly used lipid-lowering agents are excluded from the prior authorization requirements in this policy. Specifically, atorvastatin, colesevelam, colestipol, ezetimibe, and ezetimibe‑simvastatin do not have coverage requirements under this policy.

    Requests based solely on physician‑supplied samples will not satisfy the documentation requirements for a formulary exception or prior authorization. Providers must submit supporting documentation (for example, chart notes, laboratory results, or other clinical information) to demonstrate that the member meets all approval criteria; prescription claims and other historic medication records may be used to establish prior use or trial-and-failure of formulary alternatives.

    If the submitted information indicates the requested therapy is unlikely to be clinically effective for the prescribed purpose, the request may be deemed not medically necessary. In such cases, a provider may request individual consideration for an atypical patient, but the burden of documentation remains with the provider — absence of sufficient clinical documentation (including reasons precluding trials of formulary alternatives) may result in denial.

    Coding, Lab Thresholds, and Related Values

    Formulary agents listedmixed
    Evkeezaevinacumab
    Juxtapidlomitapide
    Nexletolbempedoic acid
    Nexlizetbempedoic acid and ezetimibe
    Leqvioinclisiran
    Repathaevolocumab
    Praluentalirocumab
    Tryngolzaolezarsen
    Fasting Triglyceride Threshold
    Fasting triglyceride threshold≥880 mg/dL
    Recency requirement for triglyceride valueWithin the last 12 months
    ApplicabilityRequired for Tryngolza initial approval for familial chylomicronemia syndrome
    Lab Recency Requirements
    Continuation lab recencyCurrent labs within ≤3 months required to document maintained improvement
    Initial LDL/triglyceride lab recencyRecent LDL or triglyceride labs within ≤12 months
    Leqvio initial lab requirement

    Provider Requirements, Documentation, and Prior Authorization

    Prior Authorization

    Prior authorization required; how to request

    Prior authorization is required for multiple antihyperlipidemic agents on the BCBSMA formulary. To request coverage, providers may call Pharmacy Operations (Tel: 1-800-366-7778), fax (1-800-583-6289), or submit the Formulary Exception/Prior Authorization form (Massachusetts Standard Form for Medication Prior Authorization Requests or #434).

    Prior Authorization

    PA requires meeting listed clinical criteria

    Prior authorization requests must demonstrate that the member meets the applicable initial approval or continuation criteria for the requested medication (diagnosis, recent lipid labs, specialist/lipid program evaluation where required, adherence and diet/statin adjunct requirements).

    Step Therapy

    Document reasons for exceptions to step therapy

    Background

    This policy defines prior authorization, quantity limit, and clinical coverage criteria for selected antihyperlipidemic medications on the BCBSMA formulary. It applies to commercial members (excludes Medicare Advantage) and specifies that prior authorization is required for multiple agents; in addition to meeting specific diagnosis and laboratory thresholds, requests commonly require documentation of prior use or failure of formulary alternatives and submission of supporting clinical records. Providers should use the Massachusetts Standard Form for Medication Prior Authorization Requests (eForm) or form #434 when submitting requests and may request individual consideration for atypical patients with appropriate supporting documentation.

    Definitions and Key Terms

    Maximally Tolerated Statin Therapy (implied requirement)
    DefinitionUse as adjunct to diet and maximally tolerated statin therapy (often in combination with ezetimibe); implies patient has been treated with the highest statin intensity they can tolerate or has documented intolerance
    DocumentationProvider must document prior statin treatments or reasons for intolerance/failure when required by agent-specific criteria
    Role in criteriaMaximally tolerated statin therapy is a prerequisite for coverage of multiple agents (e.g., Evkeeza, Juxtapid, Nexletol/Nexlizet) unless otherwise specified
    HeFH (Heterozygous Familial Hypercholesterolemia)
    TermHeterozygous Familial Hypercholesterolemia (HeFH)
    Context in policyListed as an accepted diagnosis for initial approval of several agents (e.g., Leqvio, Praluent, Repatha)

    Policy Revision History

    2026-03-15material_revisionLatest

    Added expanded indication for Repatha and updated formatting and references.

    2025-06-?addition

    Added Tryngolza to the policy (Tryngolza clinical guideline and initial approval criteria included).

    2025-01-?revision
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyAntihyperlipidemic agents prior authorization and quantity limits
    Policy CodePolicy 013
    Change TypeAdded Repatha indicationadded Tryngolzarevised statin trial requirement
    Effective Date
    Next Review Date
    Key ActionPrior authorization must be submitted and meet listed initial or continuation criteria with supporting documentation (labs, treatment history, and specialist evaluation when required).
    SourceLink
    On This Page
    Coverage Criteria for Antihyperlipidemic AgentsCoding, Lab Thresholds, and Related ValuesProvider Requirements, Documentation, and Prior AuthorizationBackgroundDefinitions and Key TermsPolicy Revision History

    Tryngolza adjunct requirement

    Recent LDL labs (<12 months) required for initial approval
    General initial approval lab requirementRecent LDL labs with values (<12 months) apply to initial approval criteria

    If step therapy or formulary alternatives apply, the provider must document the clinical reason preventing trial of formulary alternatives; prescription claims may be used to establish prior use or step completion.

    • Provide clinical rationale if switching to a non-formulary agent is contraindicated or inappropriate.
    • Claims history may be used to show prior trials; additional documentation required if claims do not establish prior use.
    Step Therapy

    Formulary step and failure documentation for non-covered meds

    Formulary and step requirements apply; for non-covered medications the member must have previous treatment failure with, or contraindication to, at least two covered formulary alternatives when available, in addition to meeting prior authorization criteria.

    • Non-formulary (NFNC) requests require documented failure or contraindication to ≥2 covered alternatives.
    • Higher member cost share may apply if an exception for a non-preferred/non-formulary drug is approved.
    Documentation Required

    Document alternatives tried: names, strengths, dates

    Providers must document the name and strength of formulary alternatives tried and failed, including dates if available, and provide specifics regarding the nature of the treatment failure.

    • Include medication name, strength, treatment dates (if available), and description of failure or intolerance.
    Billing Rule

    Required supporting documentation and forms

    Submit supporting documentation to show the member meets all approval criteria, such as chart notes, lab results, or genetic testing; use the Massachusetts Standard Form for Medication Prior Authorization Requests (eForm) or print and fax form #434.

    • Chart notes describing diagnosis and clinical course.
    • Recent lipid labs (within required recency: ≤12 months for initial, ≤3 months for continuation where specified).
    • Genetic testing results when required (e.g., Tryngolza: familial chylomicronemia syndrome).
    Denial Risk

    Missing documentation may trigger denial

    Failure to provide documentation of trial and failure of formulary alternatives or absence of prescription claims demonstrating use of preferred medications may result in denial of the prior authorization request.

    Denial Risk

    Sample-only requests are insufficient

    Requests based exclusively on the use of medication samples will not meet coverage criteria for an exception and may be denied if no other supporting documentation is provided.

    Use with therapyEligibility often requires evaluation in a lipid program and adjunct to maximally tolerated statin therapy
    HoFH (Homozygous Familial Hypercholesterolemia)
    TermHomozygous Familial Hypercholesterolemia (HoFH)
    Policy examplesRequired diagnosis for Evkeeza and Juxtapid initial approval criteria
    Therapy contextUse as adjunct to diet and maximally tolerated statin therapy (often with ezetimibe) is required for coverage
    Familial Chylomicronemia Syndrome
    DefinitionFamilial chylomicronemia syndrome confirmed by genetic mutation analysis
    Program evaluationEvaluation in a lipid program staffed by a board-certified cardiologist or endocrinologist is required
    Associated lab requirementFasting triglyceride levels of ≥880 mg/dL within the last 12 months required for Tryngolza initial approval

    Updated criteria to remove requirement for trial of three statins for Praluent and Repatha.

    2024-08-?addition

    Included Nexletol and Nexlizet with new indication in the policy.

    2024-07-?formulary_change

    Added Repatha to the formulary and made Praluent non-formulary/clinically managed (NFNC).